What's the Problem?

Antimicrobial resistance is one of the top ten most urgent global health challenges. 700,000 people die every year from formerly treatable infections that have developed resistance to antimicrobial drugs. If no action is taken, drug-resistant infections could cause 10 million deaths a year by 2050. Livestock production is the largest global consumer of antimicrobials and aquaculture is another significant consumer. Global livestock output could fall by more than 11% with the rise of antimicrobial resistance. By 2030, shocks due to antimicrobial resistance could cost the world up to USD 3.4 trillion a year and force an additional 24 million people into extreme poverty.

How are they Solving it?

Alytix developed a bacteriophage platform for the design of products for treating bacterial infections, including antibiotic-resistant ones. Bacteriophage are natural-occurring bacterial predators, capable of specifically attacking and killing them. Compared to antibiotics, bacteriophages generate no resistance and have no side effects. They are continuously pursuing the enhancement of the bacteriophage properties by genetic engineering, leading to better ways to treat diseases. Alytix have the necessary know-how for the development of many kinds of products against any kind of target bacteria, through a bacteriophage platform to improve health, with in-lab engineering for a better future.

Go to their website

Next Startup

Aplife Biotech

Go back to portfolio